These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

731 related items for PubMed ID: 16795969

  • 1. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY, Liang JA, Chen YK, Tsai CY, Kao CH.
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [Abstract] [Full Text] [Related]

  • 2. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
    Ozkan E, Soydal C, Araz M, Kir KM, Ibis E.
    Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
    [Abstract] [Full Text] [Related]

  • 3. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer.
    Hung GU, Shiau YC, Tsai SC, Chao TH, Ho YJ, Kao CH.
    Anticancer Res; 2001 Apr; 21(2B):1375-8. PubMed ID: 11396217
    [Abstract] [Full Text] [Related]

  • 4. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
    Sanli Y, Kuyumcu S, Ozkan ZG, Kilic L, Balik E, Turkmen C, Has D, Isik G, Asoglu O, Kapran Y, Adalet I.
    Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ability of 18F-FDG PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations.
    Kyoto Y, Momose M, Kondo C, Itabashi M, Kameoka S, Kusakabe K.
    Ann Nucl Med; 2010 Jun; 24(5):395-401. PubMed ID: 20364373
    [Abstract] [Full Text] [Related]

  • 7. Utility of low dose (18)F-FDG PET-CT in patients with suspected colorectal carcinoma recurrence in conventional diagnostic methods.
    Ochoa-Figueroa MA, Uña-Gorospe J, Allende-Riera A, Cárdenas-Negro JC, Muñoz-Iglesias J, Cabello-García D, De Sequera-Rahola M, Martínez-Gimeno E.
    Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):249-56. PubMed ID: 23067526
    [Abstract] [Full Text] [Related]

  • 8. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET).
    Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, Peeters M, Penninckx F, Filez L, Bleichrodt RP, Mortelmans L.
    Eur J Cancer; 2001 May; 37(7):862-9. PubMed ID: 11313174
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.
    Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA.
    Ann Surg; 1998 Mar; 227(3):319-23. PubMed ID: 9527052
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z, Szefer J, Zuchora Z, Romanowicz G, Pietrzak T.
    Pol Merkur Lekarski; 2004 Mar; 17 Suppl 1():63-6. PubMed ID: 15603351
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
    Lee JH, Park SG, Jee KN, Park DG, Namgung H, Song IH.
    Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [¹⁸F-FDG PET/CT. Its correlation with carcinoembryonic antigen in patients with colorectal carcinoma].
    Granados Rangel O, Estrada G, Altamirano J.
    Gac Med Mex; 2014 Jun; 150(6):509-17. PubMed ID: 25375281
    [Abstract] [Full Text] [Related]

  • 19. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
    Odalovic S, Stojiljkovic M, Sobic-Saranovic D, Pandurevic S, Brajkovic L, Milosevic I, Grozdic-Milojevic I, Artiko V.
    Neoplasma; 2017 Jun; 64(6):954-961. PubMed ID: 28895416
    [Abstract] [Full Text] [Related]

  • 20. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
    Lonneux M, Reffad AM, Detry R, Kartheuser A, Gigot JF, Pauwels S.
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.